If you guys do a deep research on UG Healthcare (Malaysia’s company listed in Singapore), you guys will realize that it is quite similar to Malaysia listed Supermax and Top Glove. The reason Supermax and Top Glove up alot since Supermax release their quarter report is because these 2 companies are distributing their own brand of glove which lead to higher profit margin. You guys can understand further from the video as per below link. After watching, you guys can go read UG's report and you guys will realize that UG has their own distribution center at China, Nigeria, UK, German, US and Brazil. Despite UG didnt own 100% of share of these companies, but definitely it helps UG to have better profit. Also, these coutries are badly affected by Covid-19.
Also, not to neglect that Ug Healthcare German is also selling mask, PPE, disinfection, protective clothes etc. All these products are high demand product during this Covid-19. Please refer to the link to understand better.
Besides, UG Healthcare Nigeria is also very interesting distribution center as it is selling the similar products that UG Healthcare German is selling but on top of that, it is also selling infra-red thermometer which is also high demand. Please refer to the link below.
The link below will enable you to understand better about Uniglove UK. Even though it is old news but it definitely will be benefited during this pandemic as it is Europe’s first antimicrobial nitrile glove.
If we do comparison between Rubberex Malaysia and UG Healthcare. UG healthcare is lagging behind. Rubberex market cap = (rm3.56/3.06) * 252195617 = SGD 293,404,051 UG heathcare market cap =(SGD 0.47 * 196092856)= SGD 92,163,642
UG yearly capacity is around 3B where Rubberex only 2B.
So if we use production capacity ratio to market cap as below calculation. UG should worth SGD (293404051 (Rubberex’s market cap) * 3B (UG’s capacity)) / 2b (Rubberex’s market cap) = 214685891
UG’s potential share price = 214685891 / 196092856 (no of UG’s issued share)= SGD 1.09
If we do comparison between Careplus Malaysia and UG Healthcare. UG healthcare is also lagging behind. Careplus market cap = (rm1.40/3.06) * 531,359,799 = SGD 243,105,790 UG heathcare market cap =(SGD 0.47 * 196092856)= SGD 92,163,642
So if we use production capacity ratio to market cap as below calculation. UG should worth SGD (243105790 (careplus’ market cap) * 3B (UG’s capacity)) / 4.1B (careplus’ capacity) = 177882285.4
UG’s potential share price = 177882285.4 / 196092856 (no of UG’s issued share) = SGD 0.907
Even though careplus produce 1B pcs extra compared to UG healthcare, but UG healthcare will benefitted from it’s own brand of glove as well as it’s distribution centers in UK, Brazil and Nigeria are selling others PPE and tools which are badly needed during this pandemic.
If we use the method of one of the Malaysia’s famous investor to calculation the price per glove, UG healthcare is on 0.09 per glove which is much more cheaper compared to peers.
Even though the last quarter report seems like “poor”, but it was mainly affected by the production modification cost where the board has decided to on hold the modification in order to cope with the sudden spike of demand. Do take note that the modification at the end will benefit the group as well. UG has reported positive earning for the last 3 FY. In fact, increase of marketing expenses is good for the company in long run as once everyone know about “Uniglove”, the marketing expenses eventually will come back and profit will go up.
Most likely August report will have flying colour result.
Hey Guys ! What is the target price UG Healthcare ? I Brought in at 0.24sen ! And now shoot up to 1.10++... Feel like it time to let go at 1.50... any thought guys ?
Another glove counter (Rubberex) in Malaysia has released QR report. It made approximate SGD 3M from January till March 2020. It's yearly capacity is only 1B++ and if it can make such profit, there is no reason UG Healthcare will make lesser than it since UG Healthcare is OBM with own distribution center in UK, German, China, Nigeria and Brazil. Also, these distribution centers are also selling other product such as mask, gown, hand santinizer, thermometer etc. All these are high demand during this pandemic.
UG healthcare is still a counter which worth to have a look...
Another glove counter (Rubberex) in Malaysia has released QR report. It made approximate SGD 3M from January till March 2020. It's yearly capacity is only 1B++ and if it can make such profit, there is no reason UG Healthcare will make lesser than it since UG Healthcare is OBM with own distribution center in UK, German, China, Nigeria and Brazil. Also, these distribution centers are also selling other product such as mask, gown, hand santinizer, thermometer etc. All these are high demand during this pandemic.
UG healthcare is still a counter which worth to have a look...
Those who holding UG healthcare really can become a Millionaire !!! Hey Bryan, what is the target price for UG healthcare ? Bassicaly which platform that you are using to see the sgx stock ? Becuase im from malaysia, i only can view it in Google
As mentioned earlier, UG Healthcare has same business model as Supermax. Both of these company are OBM and have their own distribution center at different countries.
Below link is an article produced by a famous investor in Malaysia. We can use the similar method to apply on UG Healthcare.
There is very high possibility that UG has very good first half result as the share price going up non stop.
Coincidently that all their distribution centers are located at the countries that badly affected by Covid-19 such as Brazil, US, German and Nigeria.
If we search deeper, the direction of the company seems like toward a one stop solution model. If we google Uniglove Germany or Uniglove Nigeria, we can see that these distribution centers are selling glove, mask, disinfection under it's own brand - Uniglove. Please read the links below.
Not to neglected that Uniglove UK is also selling antimicrobial glove which is high demand for this pandemic as this glove can kill gems. So far in the market, only Hartalega which listed in Bursa Malaysia produces antimicrobial glove in large scale. In short, UG healthcare will be benefitted as UK is one of the country that badly impacted by Covid-19.
In conclusion, UG overall business will be benefitted as many of the product they are selling are high demand during this pandemic.
Flip through the AR again, I realized that the founder / BOD and their family members are actually holding approximate 73.64% of the issued shares instead of what i had mentioned earlier 60%++. Hence, the liquidity in the market is less. Possible that the BOD will bonus issue or share split in the coming QR report to increase the liquidity in the market as well as expand their business. With all these, the share price may not U turn at all.
Unable to upload picture here but you guys can see the details from below link.
just checked online the selling price of Uniglove's antimicrobial glove, the selling price is crazy. It is close to USD 250 per 1000 pcs. Please refer to the link below.
Even though this selling price is from the dealer or distributor. But let's assume Uniglove is selling at USD 150 to the distributor. What kind of profit they are making??
@ kenmeng is there anything to panic? we invest is based on the company fundamental. The movement of the share price is damn solid and i suppose it is because it is OBM where better profit compared to peer. If rubberex Malaysia can make SGD3M per quarter, i doubt UG couldn't make it especially it distribution centers - Uniglove are selling other healthcare / PPE products. Cheer
So what about UG Healthcare which is OBM (Unigloves) and also have distribution centers at US, UK, German, Brazil and Nigeria? Besides glove, there are selling PPE and other healthcare products which are high demand during pandemic.
4 heavenly Kings now too rich in valuation so it won't go double or triple anymore
Maximum up side will be another 50% to 80% at most
When Supermax was Rm1.73 we bought in. Now over Rm18.00 already Up a Whopping 1,000%
Best buy now is Careplus (0163) at Rm3.30
Careplus will expand by converting its warehouse to more glove lines. Plus it bought a Budget Hotel in Negeri Sembilan to convert it into Workers' hotel
Being able to avoid Topglove bad publicity due to labour issues it has wisely bought a nice facility to create a good image for foreign media
PLUS IT HAS EXPANSION IN BRAZIL
Now with
4 Billion Medical Gloves
6 Billion by year end
8 billion by end 2021
ITS LOCATION IN SENAWANG, N SEMBILAN IS PERFECT. VERY NEAR SEPANG INTERNATIONAL AIRPORT WHICH IT CAN EXPORT ITS GLOVES WORLD WIDE
These are the 3 Super growth glove stocks of Malaysia
1. Supermax. Profit jumped by 2,500%
2. Careplus ....faster than a Cheetah
3. Hlt. This one with latest cutting edge tech of Tripple Former Dipper liners will expand to 5.3 billion high quality medical exam gloves Can expect Hlt to grow by leaps and bounds
And one more is disinfectant and sanitizer company of Malaysia called Ancom ((4758)
This counter is remained a healthcare counter which worthy for investor to look into it based on the reasons below.
1) Malaysia EPF (equivalent to Singapore’s CPF) emerge as a substantial shareholder. Even there is some disposable yesterday but EPF still holding as much as 4.9+%. There are different fund manager who managing the fund for EPF and some is short term trader and some is long term trader. Hence, the disposable is negligible since. Based on the record, EPF currently is the substantial shareholder of the big 4 (Top Glove, Harta, Kossan, Supermax) listed on Bursa and Riverstone and Ug healthcare listed on SGX. What is the reason EPF didn’t emerge as the substantial shareholder for second liner of glove maker listed on Bursa???
2) Most of the listed company from different sectors are not profit making recently. There are limited companies are making good profit such as glove maker and healthcare related.
3) Singapore is a political and currency stable country. Will foreign fund look into listed glove maker on SGX to diversity the risk???
4) From the QR and AR, the director keep mentioning the expansion can narrow the gap between their downstream and upstream. Which means the demand of Uniglove is more than the supply. Hence, the 59% increase of production output will be easily increase 50% of the net profit. Even the ASP stagnant at current level, UG Healthcare still manage to report a huge increase in revenue and net profit due to the increase of the production output by 59%.
5) Newly setup sales office at Suzhou, China show that Uniglove has better exposure in China as this is the 3rd outlet they have in China.
Despite the share price has increased few hundred %, based on the lastest AR, non of the directors reduce their holding. In fact, some has increased their holding. This prove that the directors are confident with the future of the company.
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Nallayak
310 posts
Posted by Nallayak > 2015-06-19 09:46 | Report Abuse
Thai report 1st case of Mers